Literature DB >> 34320606

Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism.

Joseph M Collins1, Danxin Wang.   

Abstract

The cytochrome P450 3A4 (CYP3A4) enzyme is the most abundant drug-metabolizing enzyme in the liver, displaying large inter-person variability with unknown causes. In this study, we found that the expression of CYP3A4 is negatively correlated with AC069294.1 (ENSG00000273407, ENST00000608397.1), a lncRNA generated antisense to CYP3A4. Knockdown of AC069294.1 in Huh7 cells increased CYP3A4 mRNA ~3-fold, whereas overexpression of AC069294.1 decreased CYP3A4 mRNA by 89%. We also observed changes in CYP3A5 expression when AC069294.1 was knocked down or overexpressed, indicating dual effects of AC069294.1 on both CYP3A4 and CYP3A5 expression. Consistently, the expression level of CYP3A5 is also negatively correlated with AC069294.1. Previous studies have shown associations between an intronic single nucleotide polymorphism CYP3A4*1G (rs2242480) and CYP3A metabolism, but the results are inconsistent and the underlying mechanism is unclear. We show here that CYP3A4*1G (rs2242480) is associated with 1.26-fold increased expression of AC069294.1 (P < 0.0001), and decreased expression of CYP3A4 by 31% (P = 0.008) and CYP3A5 by 39% (P = 0.004). CYP3A4*1G is located ~2.7 kb upstream of AC069294.1 and has been previously reported to have increased transcriptional activity in reporter gene assays. Taken together, our results demonstrate the regulation of CYP3A4 and CYP3A5 by a novel lncRNA AC069294.1. Our results also indicate that the clinically observed CYP3A4*1G associations may be caused by its effect on the expression of AC069294.1, and thereby altered expression of both CYP3A4 and CYP3A5. Furthermore, because CYP3A4*1G is in high linkage disequilibrium with CYP3A5*1, increased AC069294.1 expression caused by CYP3A4*1G may decrease expression of the normal-functioning CYP3A5*1, explaining additional inter-person variability of CYP3A5.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34320606      PMCID: PMC8578198          DOI: 10.1097/FPC.0000000000000447

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  35 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Reversible Ponceau staining as a loading control alternative to actin in Western blots.

Authors:  Isabel Romero-Calvo; Borja Ocón; Patricia Martínez-Moya; María Dolores Suárez; Antonio Zarzuelo; Olga Martínez-Augustin; Fermín Sánchez de Medina
Journal:  Anal Biochem       Date:  2010-03-03       Impact factor: 3.365

3.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.

Authors:  D Wang; Y Guo; S A Wrighton; G E Cooke; W Sadee
Journal:  Pharmacogenomics J       Date:  2010-04-13       Impact factor: 3.550

4.  A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.

Authors:  Bao-xia He; Lei Shi; Jian Qiu; Liang Tao; Rui Li; Liang Yang; Shu-jin Zhao
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-12-29       Impact factor: 4.080

5.  Cis-acting regulatory elements regulating CYP3A4 transcription in human liver.

Authors:  Joseph M Collins; Danxin Wang
Journal:  Pharmacogenet Genomics       Date:  2020-07       Impact factor: 2.089

6.  Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis.

Authors:  Dongying Li; William H Tolleson; Dianke Yu; Si Chen; Lei Guo; Wenming Xiao; Weida Tong; Baitang Ning
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2019-07-15       Impact factor: 3.781

7.  Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.

Authors:  Miwa Uesugi; Mio Hosokawa; Haruka Shinke; Emina Hashimoto; Tamotsu Takahashi; Tomoki Kawai; Kazuo Matsubara; Kohei Ogawa; Yasuhiro Fujimoto; Shinya Okamoto; Toshimi Kaido; Shinji Uemoto; Satohiro Masuda
Journal:  Biol Pharm Bull       Date:  2013       Impact factor: 2.233

8.  Patients with CYP3A4*1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection.

Authors:  Huidong Zhang; Minghao Chen; Xiaodong Wang; Songyang Yu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

9.  Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.

Authors:  Chuan-Jiang Li; Liang Li; Li Lin; Hai-Xia Jiang; Ze-Yan Zhong; Wei-Mo Li; Yan-Jun Zhang; Ping Zheng; Xu-Hui Tan; Lin Zhou
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  Highly Variable Expression of ESR1 Splice Variants in Human Liver: Implication in the Liver Gene Expression Regulation and Inter-Person Variability in Drug Metabolism and Liver Related Diseases.

Authors:  J W Sun; J M Collins; D Ling; D Wang
Journal:  J Mol Genet Med       Date:  2019-09-30
View more
  2 in total

Review 1.  Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.

Authors:  Qinglian Zhai; Maaike van der Lee; Teun van Gelder; Jesse J Swen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 2.  PharmVar GeneFocus: CYP3A5.

Authors:  Cristina Rodriguez-Antona; Jessica L Savieo; Volker M Lauschke; Katrin Sangkuhl; Britt I Drögemöller; Danxin Wang; Ron H N van Schaik; Andrei A Gilep; Arul P Peter; Erin C Boone; Bronwyn E Ramey; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2022-02-24       Impact factor: 6.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.